Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Combined-modality therapies for non-small cell lung cancer
C. P. Belani, J. Aisner
Department of Medicine
Division of Hematology and Oncology
Penn State Cancer Institute
Cancer Institute, Next-Generation Therapies
Research output
:
Contribution to journal
›
Article
›
peer-review
7
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Combined-modality therapies for non-small cell lung cancer'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Advanced Stage
33%
Cancer Center
33%
Carboplatin
33%
Chemotherapy
100%
Cisplatin
33%
Combination Chemotherapy
100%
Combined Modality
33%
Combined Modality Therapy
100%
Concurrent Cisplatin
33%
Concurrent Radiotherapy
33%
Concurrent Use
33%
Early Disease
33%
Improved Survival
33%
Local Control
66%
Local Survival
33%
Long-term Survival
33%
Long-term Survivors
33%
Low-dose Radiation
33%
Median Survival
33%
Non-small Cell Lung Cancer (NSCLC)
100%
Ongoing Clinical Trials
66%
Potential Gains
33%
Radiotherapy
100%
Radiotherapy Alone
66%
Randomized Trial
33%
Response Rate
33%
Stage III Disease
33%
Stage III Non-small Cell Lung Cancer
66%
Stage IV Disease
66%
Survival Duration
66%
Survival Rate
33%
Time to Treatment Failure
33%
Treatment Programs
33%
University of Maryland
33%
Medicine and Dentistry
Carboplatin
14%
Cisplatin
28%
Clinical Trial
28%
Combination Chemotherapy
14%
Diseases
57%
Long Term Survival
14%
Low Drug Dose
14%
Malignant Neoplasm
14%
Multimodality Cancer Therapy
100%
Non Small Cell Lung Cancer
100%
Radiation Therapy
100%
Time to Treatment
14%
Pharmacology, Toxicology and Pharmaceutical Science
Carboplatin
16%
Chemotherapy
100%
Cisplatin
33%
Clinical Trial
33%
Diseases
66%
Long Term Survival
16%
Malignant Neoplasm
16%
Non Small Cell Lung Cancer
100%
Immunology and Microbiology
Long Term Survival
100%
Low Drug Dose
100%
Neuroscience
Carboplatin
14%
Cisplatin
28%
Radiation Therapy
100%
Agricultural and Biological Sciences
Lung
100%